Construction of a ferroptosis scoring system and identification of LINC01572 as a novel ferroptosis suppressor in lung adenocarcinoma

Background: Ferroptosis is a novel process of programmed cell death driven by excessive lipid peroxidation that is associated with the development of lung adenocarcinoma. N6-methyladenosine (m6a) modification of multiple genes is involved in regulating the ferroptosis process, while the predictive value of N6-methyladenosine- and ferroptosis-associated lncRNA (FMRlncRNA) in the prognosis of patients remains with LUAD remains unknown. Methods: Unsupervised cluster algorithm was applied to generate subcluster in LUAD according to ferroptosis-associated lncRNA. Stepwise Cox analysis and LASSO algorithm were applied to develop a prognostic model. Cellular location was detected by single-cell analysis. Also, we conducted Gene set enrichment analysis (GSEA) enrichment, immune microenvironment and drug sensitivity analysis. In addition, the expression and function of the LINC01572 were investigated by several in vitro experiments including qRT-PCR, cell viability assays and ferroptosis assays. Results: A novel ferroptosis-associated lncRNAs-based molecular subtype containing two subclusters were determined in LUAD. Then, we successfully created a risk model according to five ferroptosis-associated lncRNAs (LINC00472, MBNL1-AS1, LINC01572, ZFPM2-AS1, and TMPO-AS1). Our nominated model had good stability and predictive function. The expression patterns of five ferroptosis-associated lncRNAs were confirmed by polymerase chain reaction (PCR) in LUAD cell lines. Knockdown of LINC01572 significantly inhibited cell viability and induced ferroptosis in LUAD cell lines. Conclusion: Our data provided a risk score system based on ferroptosis-associated lncRNAs with prognostic value in LUAD. Moreover, LINC01572 may serve as a novel ferroptosis suppressor in LUAD.

[1]  Kaibin Zhu,et al.  Down-regulated m6A reader FTO destabilizes PHF1 that triggers enhanced stemness capacity and tumor progression in lung adenocarcinoma , 2022, Cell Death Discovery.

[2]  Wen Liu,et al.  N1-Methyladenosine-Related lncRNAs Are Potential Biomarkers for Predicting Prognosis and Immune Response in Uterine Corpus Endometrial Carcinoma , 2022, Oxidative medicine and cellular longevity.

[3]  Linfeng Li,et al.  m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression , 2022, Cell Death & Disease.

[4]  Wen Liu,et al.  Crosstalk of Redox-Related Subtypes, Establishment of a Prognostic Model and Immune Responses in Endometrial Carcinoma , 2022, Cancers.

[5]  Hongyu Zhao,et al.  Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma , 2022, Frontiers in Oncology.

[6]  Minmin Shi,et al.  LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma , 2022, Journal of Hematology & Oncology.

[7]  Xianfeng Ding,et al.  Long Non-coding RNA ZFPM2-AS1: A Novel Biomarker in the Pathogenesis of Human Cancers , 2022, Molecular Biotechnology.

[8]  Yiming Xu,et al.  METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m6A modification , 2022, Cancer cell international.

[9]  R. Geng,et al.  Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC , 2022, Molecular therapy. Nucleic acids.

[10]  M. Weng,et al.  Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer , 2021, Journal of advanced research.

[11]  Feng Zhang,et al.  N6-methyladenosine modification regulates ferroptosis through autophagy signaling pathway in hepatic stellate cells , 2021, Redox biology.

[12]  W. Cao,et al.  RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma , 2021, Journal of experimental & clinical cancer research : CR.

[13]  XiaoLi Yang,et al.  Gene and prognostic value of N6-methyladenosine (m6A) modification regulatory factors in lung adenocarcinoma , 2021, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[14]  Lin Chen,et al.  Neutrophil extracellular traps in gastrointestinal cancer , 2021, World journal of gastroenterology.

[15]  Qingguo Li,et al.  A Novel Ferroptosis-Related Biomarker Signature to Predict Overall Survival of Esophageal Squamous Cell Carcinoma , 2021, Frontiers in Molecular Biosciences.

[16]  Hong-yan Cheng,et al.  Integrated Analysis of Cell Cycle–Related and Immunity-Related Biomarker Signatures to Improve the Prognosis Prediction of Lung Adenocarcinoma , 2021, Frontiers in Oncology.

[17]  F. Mechta-Grigoriou,et al.  Role of cancer‐associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer , 2021, Immunological reviews.

[18]  Bingya Liu,et al.  LncRNA MALAT1 promotes gastric cancer progression via inhibiting autophagic flux and inducing fibroblast activation , 2021, Cell Death & Disease.

[19]  M. Doyle,et al.  Interfacing Seurat with the R tidy universe , 2021, bioRxiv.

[20]  X. Zhang,et al.  Targeting SLC3A2 subunit of system XC- is essential for m6A reader YTHDC2 to be an endogenous ferroptosis inducer in lung adenocarcinoma. , 2021, Free radical biology & medicine.

[21]  Shan Mi,et al.  m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma , 2021, Briefings Bioinform..

[22]  Sheng Wang,et al.  Upregulation of CENPM facilitates lung adenocarcinoma progression via PI3K/AKT/mTOR signaling pathway , 2021, Acta biochimica et biophysica Sinica.

[23]  Rusong Yang,et al.  A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma , 2021, Bioengineered.

[24]  Jinhui Liu,et al.  Development of a novel immune-related lncRNA signature as a prognostic classifier for endometrial carcinoma , 2021, International journal of biological sciences.

[25]  N. Jia,et al.  LINC01572 Regulates Cisplatin Resistance in Gastric Cancer Cells by Mediating miR-497-5p , 2020, OncoTargets and therapy.

[26]  W. Xue,et al.  Hypoxia-induced GBE1 expression promotes tumor progression through metabolic reprogramming in lung adenocarcinoma , 2020, Signal Transduction and Targeted Therapy.

[27]  Jingqun Tang,et al.  CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c‐Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma , 2020, Thoracic cancer.

[28]  S. Ju,et al.  The potential role of RNA N6-methyladenosine in Cancer progression , 2020, Molecular Cancer.

[29]  G. Cao,et al.  Down-regulation of MBNL1-AS1 contributes to tumorigenesis of NSCLC via sponging miR-135a-5p. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[30]  R. Sun,et al.  Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[31]  Xiao-Li Zhu,et al.  LncRNA ZFPM2‐AS1 promotes lung adenocarcinoma progression by interacting with UPF1 to destabilize ZFPM2 , 2020, Molecular oncology.

[32]  A. Berghoff,et al.  New emerging targets in cancer immunotherapy: CD27 (TNFRSF7) , 2020, ESMO Open.

[33]  Gang Yin,et al.  Functions of N6-methyladenosine and its role in cancer , 2019, Molecular Cancer.

[34]  Gang Yin,et al.  Functions of N6-methyladenosine and its role in cancer , 2019, Molecular Cancer.

[35]  Q. Kan,et al.  The interplay between m6A RNA methylation and noncoding RNA in cancer , 2019, Journal of Hematology & Oncology.

[36]  Shizhen Zhang,et al.  CircRNA-ENO1 promoted glycolysis and tumor progression in lung adenocarcinoma through upregulating its host gene ENO1 , 2019, Cell Death & Disease.

[37]  B. Li,et al.  Ferroptosis, a new form of cell death: opportunities and challenges in cancer , 2019, Journal of Hematology & Oncology.

[38]  T. Lei,et al.  Screening key lncRNAs for human lung adenocarcinoma based on machine learning and weighted gene co-expression network analysis. , 2019, Cancer biomarkers : section A of Disease markers.

[39]  F. Garrido HLA Class-I Expression and Cancer Immunotherapy. , 2019, Advances in experimental medicine and biology.

[40]  N. Razavian,et al.  Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning , 2018, Nature Medicine.

[41]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[42]  Aifu Lin,et al.  Membrane-lipid associated lncRNA: A new regulator in cancer signaling. , 2018, Cancer letters.

[43]  M. Berger,et al.  Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy , 2018, Science.

[44]  B. Zhivotovsky,et al.  Cell death-based treatment of lung adenocarcinoma , 2018, Cell Death & Disease.

[45]  Y. Mo,et al.  LncRNA-mediated regulation of cell signaling in cancer , 2017, Oncogene.

[46]  Gang Chen,et al.  Clinical roles of the aberrantly expressed lncRNAs in lung squamous cell carcinoma: a study based on RNA-sequencing and microarray data mining , 2017, Oncotarget.

[47]  M. Schön,et al.  Neutrophil extracellular traps: protagonists of cancer progression? , 2017, Oncogene.

[48]  Yun-hui Li,et al.  Integrated analysis of long non-coding RNA‑associated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma. , 2016, International journal of oncology.

[49]  D-S Li,et al.  Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma. , 2016, European review for medical and pharmacological sciences.

[50]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[51]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[52]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[53]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[54]  C. Antonescu,et al.  KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.

[55]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[56]  Howard Y. Chang,et al.  Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.

[57]  Alberto Mantovani,et al.  Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.

[58]  A. Woltman,et al.  Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. , 1999, Journal of immunology.